SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

NI-1801 Follow-Up Reports Durable Survival Benefit at 24 Months

Updated Phase 1/1b data on NI-1801 in platinum-resistant ovarian cancer were presented in an oral presentation.

Related stories